Point-of-Care Diagnostics Market 2018-2024
Global Point-of-Care Diagnostics Market – Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2018–2024
Overview: Point-of-care diagnostic test, also referred to as bedside testing or near-patient testing, is a medical diagnostic test conducted outside the laboratory at or near the place where the patient is receiving care. These tests are usually performed by non-laboratory personnel and test results are used for clinical decision making. The complexity and procedures for POC diagnostics may vary from manual methodologies to automated analyzers. These tests are comparatively more expensive than typical laboratory tests but are convenient and cost effective in some clinical settings since these are performed in close proximity to the patient. The best part is that these tests give immediate decisions for clinical management. According to a report released by the Centers for Disease Control and Prevention (CDC), in US alone currently more than 100 million adults are living with diabetes or prediabetes. Cardiovascular diseases (CVD) account for approximately 800,000 deaths in the US. On average, one person dies from CVD every 40 seconds in the US. CVD also causes 3.9 million deaths in Europe and over 1.8 million deaths in the European Union. There is an increase in life style diseases and developing countries are also suffering from such ailments. It is primarily because of the increasing adoption of Western lifestyle which is expected to fuel the growth of point-of-care diagnostics market in near future.
The point-of-care diagnostics market is booming due to several factors such as the growing patient base for lifestyle diseases globally, growing elderly population, increasing prevalence of infectious disease, technological innovations and increasing adoption of point-of-care diagnostics. Stringent approval processes, unfavorable reimbursement scenarios and product recalls are some of the factors hampering the market growth. The market in emerging countries is expected to grow at a rapid pace during the forecast period because of increasing healthcare awareness towards point-of-care diagnostics, increasing healthcare spending and growing patient pool.
Market Analysis: The “Global Point-of-Care Diagnostics Market” is estimated to witness a CAGR of 7.7% during the forecast period 2018–2024. The market is analyzed based on four segments –products, prescription mode, end-users and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is set to be the leading region for the Point-of-Care Diagnostics market growth followed by Europe, Asia Pacific and the rest of the world.
Product Analysis: The global Point-of-Care Diagnostics market by product is segmented into glucose monitoring kits, infectious diseases testing kits, pregnancy and fertility testing kits, hematology testing kits, cardiometabolic monitoring kits, urinalysis testing kits, coagulation monitoring kits, tumor/cancer markers, cholesterol test strips, drugs-of-abuse testing kits, and others. Glucose monitoring kits occupied the largest share in 2017 due to factors such as an increase in the prevalence of diabetes, change in lifestyle, growing elderly population and increasing demand for disease management.
Prescription Mode Analysis: The global point-of-care diagnostics market by prescription mode is segmented into Prescription-based POC diagnostics and OTC-based POC diagnostics. The latter has occupied a major market share since 2017 and is expected to retain its position during the forecasted period with the introduction of hand-held and portable devices and increased awareness of POC diagnostics.
End-Users Analysis: The global point-of-care diagnostics market by end-users is segmented into hospitals, clinics, home-care and others. Hospitals occupied the maximum market share in 2017 and is expected to be same for the next few years.
Key Players: Abbott Laboratories, F. Hoffmann-La Roche, Johnson & Johnson, Siemens AG, Danaher Corporation, Qiagen N.V., BioMerieux S.A., Nova Biomedical, Beckton Dickinson and Company, Trinity Biotech plc and other niche players.
Competitive Analysis: Currently, the glucose monitoring kits dominate the global point-of-care diagnostics market. A lot of new players are concentrating on this market to deliver advanced and innovative products. The key market players are acquiring other companies to enhance their product portfolio and strengthen their leadership position in the market. For instance, in October 2017, Abbott completed the acquisition of Alere for about $5.3 billion. In January 2017, Werfen acquired Accriva Diagnostics, a global leader in in vitro diagnostic (IVD) blood testing at the Point-of-Care (POC). The acquisition included Accriva’s flagship product portfolio spanning coagulation, platelet aggregation, CO-Oximetry and incision devices. Not only this but key players are also launching new products to have an edge in the market. For instance, in January 2018, Abbott Laboratories announced the launch of CE marked Alinity h-series integrated system for hematology testing.
Benefits: The report provides complete details about the usage and adoption rate of point-of-care diagnostics products in various regions. With the help of this report, key stakeholders will find extensive details about the major trends, drivers, investments and vertical players’ initiatives. It will also shed light on government initiatives toward the test adoption in the upcoming years along with the details of commercial tests available in the market. Moreover, the report provides details about the major challenges that are going to have an impact on the market growth. Additionally, the report gives in-depth information about the key business opportunities to key stakeholders so that they can expand their businesses and forecast the revenue in specific verticals before investing or expanding their businesses in this market.
Key Stakeholders:
Overview: Point-of-care diagnostic test, also referred to as bedside testing or near-patient testing, is a medical diagnostic test conducted outside the laboratory at or near the place where the patient is receiving care. These tests are usually performed by non-laboratory personnel and test results are used for clinical decision making. The complexity and procedures for POC diagnostics may vary from manual methodologies to automated analyzers. These tests are comparatively more expensive than typical laboratory tests but are convenient and cost effective in some clinical settings since these are performed in close proximity to the patient. The best part is that these tests give immediate decisions for clinical management. According to a report released by the Centers for Disease Control and Prevention (CDC), in US alone currently more than 100 million adults are living with diabetes or prediabetes. Cardiovascular diseases (CVD) account for approximately 800,000 deaths in the US. On average, one person dies from CVD every 40 seconds in the US. CVD also causes 3.9 million deaths in Europe and over 1.8 million deaths in the European Union. There is an increase in life style diseases and developing countries are also suffering from such ailments. It is primarily because of the increasing adoption of Western lifestyle which is expected to fuel the growth of point-of-care diagnostics market in near future.
The point-of-care diagnostics market is booming due to several factors such as the growing patient base for lifestyle diseases globally, growing elderly population, increasing prevalence of infectious disease, technological innovations and increasing adoption of point-of-care diagnostics. Stringent approval processes, unfavorable reimbursement scenarios and product recalls are some of the factors hampering the market growth. The market in emerging countries is expected to grow at a rapid pace during the forecast period because of increasing healthcare awareness towards point-of-care diagnostics, increasing healthcare spending and growing patient pool.
Market Analysis: The “Global Point-of-Care Diagnostics Market” is estimated to witness a CAGR of 7.7% during the forecast period 2018–2024. The market is analyzed based on four segments –products, prescription mode, end-users and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is set to be the leading region for the Point-of-Care Diagnostics market growth followed by Europe, Asia Pacific and the rest of the world.
Product Analysis: The global Point-of-Care Diagnostics market by product is segmented into glucose monitoring kits, infectious diseases testing kits, pregnancy and fertility testing kits, hematology testing kits, cardiometabolic monitoring kits, urinalysis testing kits, coagulation monitoring kits, tumor/cancer markers, cholesterol test strips, drugs-of-abuse testing kits, and others. Glucose monitoring kits occupied the largest share in 2017 due to factors such as an increase in the prevalence of diabetes, change in lifestyle, growing elderly population and increasing demand for disease management.
Prescription Mode Analysis: The global point-of-care diagnostics market by prescription mode is segmented into Prescription-based POC diagnostics and OTC-based POC diagnostics. The latter has occupied a major market share since 2017 and is expected to retain its position during the forecasted period with the introduction of hand-held and portable devices and increased awareness of POC diagnostics.
End-Users Analysis: The global point-of-care diagnostics market by end-users is segmented into hospitals, clinics, home-care and others. Hospitals occupied the maximum market share in 2017 and is expected to be same for the next few years.
Key Players: Abbott Laboratories, F. Hoffmann-La Roche, Johnson & Johnson, Siemens AG, Danaher Corporation, Qiagen N.V., BioMerieux S.A., Nova Biomedical, Beckton Dickinson and Company, Trinity Biotech plc and other niche players.
Competitive Analysis: Currently, the glucose monitoring kits dominate the global point-of-care diagnostics market. A lot of new players are concentrating on this market to deliver advanced and innovative products. The key market players are acquiring other companies to enhance their product portfolio and strengthen their leadership position in the market. For instance, in October 2017, Abbott completed the acquisition of Alere for about $5.3 billion. In January 2017, Werfen acquired Accriva Diagnostics, a global leader in in vitro diagnostic (IVD) blood testing at the Point-of-Care (POC). The acquisition included Accriva’s flagship product portfolio spanning coagulation, platelet aggregation, CO-Oximetry and incision devices. Not only this but key players are also launching new products to have an edge in the market. For instance, in January 2018, Abbott Laboratories announced the launch of CE marked Alinity h-series integrated system for hematology testing.
Benefits: The report provides complete details about the usage and adoption rate of point-of-care diagnostics products in various regions. With the help of this report, key stakeholders will find extensive details about the major trends, drivers, investments and vertical players’ initiatives. It will also shed light on government initiatives toward the test adoption in the upcoming years along with the details of commercial tests available in the market. Moreover, the report provides details about the major challenges that are going to have an impact on the market growth. Additionally, the report gives in-depth information about the key business opportunities to key stakeholders so that they can expand their businesses and forecast the revenue in specific verticals before investing or expanding their businesses in this market.
Key Stakeholders:
1 INDUSTRY OUTLOOK
1.1 Industry overview
1.2 Total addressable market
1.3 Industry Trends
2 REPORT OUTLINE
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 MARKET SNAPSHOT
3.1 Market Definition – Infoholic Research
3.2 Advantages of Point-of-care testing
3.3 Disadvantages of Point-of-care testing
3.4 Segmented Addressable Market (SAM)
3.5 Trends of the point-of-Care diagnostics market
3.6 Related Markets
3.6.1 Molecular diagnostics
3.6.2 Infectious disease diagnostics
4 MARKET OUTLOOK
4.1 Overview
4.2 Funding scenario
4.3 Market segmentation
4.4 PEST Analysis
4.5 Porter 5(Five) Forces
5 MARKET CHARACTERISTICS
5.1 DRO – Global Point-of-care Diagnostics Market Dynamics
5.1.1 Drivers
5.1.1.1 Increasing prevalence of infectious disease
5.1.1.2 Growing incidence of life-style disease
5.1.1.3 Technological innovations
5.1.1.4 Increasing adoption of point-of-care diagnostics
5.1.2 Opportunities
5.1.2.1 Growth opportunities in emerging markets
5.1.2.2 Increasing awareness towards point-of-care diagnostics in developing countries
5.1.3 Restraints
5.1.3.1 Stringent approval process
5.1.3.2 Product recalls
5.1.3.3 Unfavorable reimbursement scenario
6 PRODUCT: MARKET SIZE AND ANALYSIS
6.1 Overview
6.2 Glucose monitoring kits
6.3 Infectious disease testing kits
6.4 Pregnancy and fertility testing kits
6.5 Hematology testing kits
6.6 Cardiometabolic monitoring kits
6.7 Urinalysis testing kits
6.8 Coagulation monitoring kits
6.9 Tumour or cancer marker testing kits
6.10 Cholesterol testing kits
6.11 Drugs of abuse testing kits
6.12 Others
7 PRESCRIPTION MODE: MARKET SIZE AND ANALYSIS
7.1 Overview
7.2 Prescription-based point-of-care diagnostics
7.3 Over the counter-based point-of-care diagnostics
8 END USERS: MARKET SIZE AND ANALYSIS
8.1 Overview
8.2 Hospitals
8.3 Clinics
8.4 Home-care
8.5 Others
9 REGIONS: MARKET SIZE AND ANALYSIS
9.1 Overview
9.2 North America
9.2.1 Overview
9.2.2 US
9.2.3 Canada
9.3 Europe
9.3.1 Overview
9.3.2 UK
9.3.3 Germany
9.3.4 France
9.3.5 Spain
9.4 APAC
9.4.1 Overview
9.4.2 India
9.4.3 China
9.5 Rest of the World
10 COMPETITIVE LANDSCAPE
10.1 Overview
11 VENDOR PROFILES
11.1 Abbott Laboratories
11.1.1 Overview
11.1.2 Business Unit
11.1.3 Geographic Presence
11.1.4 Business Focus
11.1.5 SWOT Analysis
11.1.6 Business Strategy
11.2 F.Hoffmann-La Roche Ltd
11.2.1 Overview
11.2.2 Business Unit
11.2.3 Geographic Presence
11.2.4 Business Focus
11.2.5 SWOT Analysis
11.2.6 Business Strategy
11.3 Johnson & Johnson
11.3.1 Overview
11.3.2 Business Units
11.3.3 Geographic Revenue
11.3.4 Business Focus
11.3.5 SWOT Analysis
11.3.6 Business Strategies
11.4 Danaher Corporation
11.4.1 Overview
11.4.2 Business Unit
11.4.3 Geographic Presence
11.4.4 Business Focus
11.4.5 SWOT Analysis
11.4.6 Business Strategy
11.5 Siemens Healthineers Inc. (Siemens AG)
11.5.1 Overview
11.5.2 Business Units
11.5.3 Geographic Presence
11.5.4 Business Focus
11.5.5 SWOT Analysis
11.5.6 Business Strategy
12 COMPANIES TO WATCH FOR
12.1 Trinity Biotech plc
12.1.1 Overview
12.1.2 Trinity Biotech plc: Recent Developments
12.2 Qiagen N.V.
12.2.1 Overview
12.2.2 Qiagen N.V.: Recent Developments
12.3 BioMerieux S.A.
12.3.1 Overview
12.3.2 BioMerieux S.A.: Recent Developments
12.4 OraSure Technologies, Inc.
12.4.1 Overview
12.4.2 OraSure Technologies, Inc.: Recent Developments
12.5 Instrumentation Laboratory (a Werfen company)
12.5.1 Overview
12.5.2 Instrumentation Laboratory: Recent Developments
12.6 Becton Dickinson and Company
12.6.1 Overview
12.6.2 Becton dickenson and company: Recent Developments
12.7 Nova Biomedical
12.7.1 Overview
12.7.2 Nova Biomedical: Recent Developments
13 ANNEXURE
13.1 Abbreviations
Tables
Table 1 FUNDING SCENARIO
Table 1 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCTS, 2017–2024 ($MILLION)
Table 1 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE, 2017–2024 ($MILLION)
Table 2 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET REVENUE BY REGIONS, 2017–2024 ($MILLION)
Table 3 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET BY VENDOR RANKING, 2017
Table 4 OTHER PROMINENT VENDORS OF POINT-OF-CARE DIAGNOSTICS MARKET
Table 5 ABBOTT LABORATORIES: PRODUCT OFFERINGS
Table 6 ABBOTT LABORATORIES: RECENT DEVELOPMENTS
Table 7 F. HOFFMANN-LA ROCHE: OFFERINGS
Table 8 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS
Table 9 JOHNSON & JOHNSON: PRODUCT OFFERINGS
Table 10 JOHNSON & JOHNSON: RECENT DEVELOPMENTS
Table 11 DANAHER CORPORATION: OFFERINGS
Table 12 DANAHER CORPORATION: RECENT DEVELOPMENTS
Table 13 SIEMENS HEALTHINEERS INC.: RECENT DEVELOPMENTS
Table 14 SIEMENS HEALTHINEERS INC.: RECENT DEVELOPMENTS
Table 15 TRINITY BIOTECH PLC: SNAPSHOT
Table 16 QIAGEN N.V.: SNAPSHOT
Table 17 BIOMERIEUX S.A.: SNAPSHOT
Table 18 ORASURES TECHNOLOGIES: SNAPSHOT
Table 19 INSTRUMENTATION LABORATORY: SNAPSHOT
Table 20 BECTON DICKINSON AND COMPANY: SNAPSHOT
Table 21 NOVA BIOMEDICAL: SNAPSHOT
?
Charts
Chart 1 RESEARCH METHODOLOGY OF GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET
Chart 2 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET REVENUE, 2017–2024 ($MILLION)
Chart 3 PEST ANALYSIS OF GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET
Chart 4 PORTER 5 FORCES ON GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET
Chart 5 DRO – IMPACT ANALYSIS OF GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET
Chart 6 KEY STAKEHOLDERS
Chart 7 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET BY PRODUCT, 2017 V/S 2024 ($)
Chart 8 GLOBAL GLUCOSE MONITORING KITS MARKET REVENUE FORECAST, 2017–2024 ($MILLION)
Chart 9 GLOBAL INFECTIOUS DISEASE TESTING KITS MARKET REVENUE FORECAST, 2017–2024 ($MILLION)
Chart 10 GLOBAL PREGNANCY AND FERTILITY TESTING KITS MARKET REVENUE FORECAST, 2017–2024 ($MILLION)
Chart 11 GLOBAL HEMATOLOGY TESTING KITS MARKET REVENUE FORECAST, 2017–2024 ($MILLION)
Chart 12 GLOBAL CARDIOMETABOLIC MONITORING KITS MARKET REVENUE FORECAST, 2017–2024 ($MILLION)
Chart 13 GLOBAL URINALYSIS TESTING KITS MARKET REVENUE FORECAST, 2017–2024 ($MILLION)
Chart 14 GLOBAL COAGULATION MONITORING KITS MARKET REVENUE FORECAST, 2017–2024 ($MILLION)
Chart 15 GLOBAL TUMOUR OR CANCER MARKER TESTING KITS MARKET REVENUE FORECAST, 2017–2024 ($MILLION)
Chart 16 GLOBAL CHOLESTEROL TESTING KITS MARKET REVENUE FORECAST, 2017–2024 ($MILLION)
Chart 17 GLOBAL DRUGS OF ABUSE TESTING KITS MARKET REVENUE FORECAST, 2017–2024 ($MILLION)
Chart 18 GLOBAL OTHERS MARKET REVENUE FORECAST, 2017–2024 ($MILLION)
Chart 19 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET BY PRESCRIPTION MODE, 2017 (%)
Chart 20 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET BY PRESCRIPTION MODE, 2024 (%)
Chart 21 GLOBAL PRESCRIPTION-BASED POINT-OF-CARE DIAGNOSTICS MARKET REVENUE FORECAST, 2017–2024 ($MILLION)
Chart 22 GLOBAL OTC-BASED POINT-OF-CARE DIAGNOSTICS MARKET REVENUE FORECAST, 2017–2024 ($MILLION)
Chart 23 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET BY END-USERS SEGMENTATION, 2017 (%)
Chart 24 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET BY GEOGRAPHICAL SEGMENTATION, 2017 (%)
Chart 25 POINT-OF-CARE DIAGNOSTICS MARKET REVENUE IN NORTH AMERICA, 2017–2024 ($MILLION)
Chart 26 POINT-OF-CARE DIAGNOSTICS MARKET REVENUE IN EUROPE, 2017–2024 ($MILLION)
Chart 27 POINT-OF-CARE DIAGNOSTICS REVENUE IN ASIA-PACIFIC, 2017–2024 ($MILLION)
Chart 28 POINT-OF-CARE DIAGNOSTICS MARKET REVENUE IN REST OF THE WORLD, 2017–2024 ($MILLION)
Chart 29 ABBOTT LABORATORIES.: OVERVIEW SNAPSHOT
Chart 30 ABBOTT LABORATORIES.: BUSINESS UNITS
Chart 31 ABBOTT LABORATORIES: GEOGRAPHIC PRESENCE
Chart 32 ABBOTT LABORATORIES.: SWOT ANALYSIS
Chart 37 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT
Chart 38 JOHNSON & JOHNSON: BUSINESS UNITS
Chart 39 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE
Chart 40 JOHNSON & JOHNSON: SWOT ANALYSIS
Chart 41 DANAHER CORPORATION: OVERVIEW SNAPSHOT
Chart 42 DANAHER CORPORATION: BUSINESS UNITS
Chart 43 DANAHER CORPORATION: GEOGRAPHIC PRESENCE
Chart 44 DANAHER CORPORATION: SWOT ANALYSIS
Chart 45 SIEMENS AG: OVERVIEW SNAPSHOT
Chart 46 SIEMENS AG: BUSINESS UNITS
Chart 47 SIEMENS AG: GEOGRAPHIC PRESENCE
Chart 48 SIEMENS HEALTHINEERS INC.: SWOT ANALYSIS
1.1 Industry overview
1.2 Total addressable market
1.3 Industry Trends
2 REPORT OUTLINE
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 MARKET SNAPSHOT
3.1 Market Definition – Infoholic Research
3.2 Advantages of Point-of-care testing
3.3 Disadvantages of Point-of-care testing
3.4 Segmented Addressable Market (SAM)
3.5 Trends of the point-of-Care diagnostics market
3.6 Related Markets
3.6.1 Molecular diagnostics
3.6.2 Infectious disease diagnostics
4 MARKET OUTLOOK
4.1 Overview
4.2 Funding scenario
4.3 Market segmentation
4.4 PEST Analysis
4.5 Porter 5(Five) Forces
5 MARKET CHARACTERISTICS
5.1 DRO – Global Point-of-care Diagnostics Market Dynamics
5.1.1 Drivers
5.1.1.1 Increasing prevalence of infectious disease
5.1.1.2 Growing incidence of life-style disease
5.1.1.3 Technological innovations
5.1.1.4 Increasing adoption of point-of-care diagnostics
5.1.2 Opportunities
5.1.2.1 Growth opportunities in emerging markets
5.1.2.2 Increasing awareness towards point-of-care diagnostics in developing countries
5.1.3 Restraints
5.1.3.1 Stringent approval process
5.1.3.2 Product recalls
5.1.3.3 Unfavorable reimbursement scenario
6 PRODUCT: MARKET SIZE AND ANALYSIS
6.1 Overview
6.2 Glucose monitoring kits
6.3 Infectious disease testing kits
6.4 Pregnancy and fertility testing kits
6.5 Hematology testing kits
6.6 Cardiometabolic monitoring kits
6.7 Urinalysis testing kits
6.8 Coagulation monitoring kits
6.9 Tumour or cancer marker testing kits
6.10 Cholesterol testing kits
6.11 Drugs of abuse testing kits
6.12 Others
7 PRESCRIPTION MODE: MARKET SIZE AND ANALYSIS
7.1 Overview
7.2 Prescription-based point-of-care diagnostics
7.3 Over the counter-based point-of-care diagnostics
8 END USERS: MARKET SIZE AND ANALYSIS
8.1 Overview
8.2 Hospitals
8.3 Clinics
8.4 Home-care
8.5 Others
9 REGIONS: MARKET SIZE AND ANALYSIS
9.1 Overview
9.2 North America
9.2.1 Overview
9.2.2 US
9.2.3 Canada
9.3 Europe
9.3.1 Overview
9.3.2 UK
9.3.3 Germany
9.3.4 France
9.3.5 Spain
9.4 APAC
9.4.1 Overview
9.4.2 India
9.4.3 China
9.5 Rest of the World
10 COMPETITIVE LANDSCAPE
10.1 Overview
11 VENDOR PROFILES
11.1 Abbott Laboratories
11.1.1 Overview
11.1.2 Business Unit
11.1.3 Geographic Presence
11.1.4 Business Focus
11.1.5 SWOT Analysis
11.1.6 Business Strategy
11.2 F.Hoffmann-La Roche Ltd
11.2.1 Overview
11.2.2 Business Unit
11.2.3 Geographic Presence
11.2.4 Business Focus
11.2.5 SWOT Analysis
11.2.6 Business Strategy
11.3 Johnson & Johnson
11.3.1 Overview
11.3.2 Business Units
11.3.3 Geographic Revenue
11.3.4 Business Focus
11.3.5 SWOT Analysis
11.3.6 Business Strategies
11.4 Danaher Corporation
11.4.1 Overview
11.4.2 Business Unit
11.4.3 Geographic Presence
11.4.4 Business Focus
11.4.5 SWOT Analysis
11.4.6 Business Strategy
11.5 Siemens Healthineers Inc. (Siemens AG)
11.5.1 Overview
11.5.2 Business Units
11.5.3 Geographic Presence
11.5.4 Business Focus
11.5.5 SWOT Analysis
11.5.6 Business Strategy
12 COMPANIES TO WATCH FOR
12.1 Trinity Biotech plc
12.1.1 Overview
12.1.2 Trinity Biotech plc: Recent Developments
12.2 Qiagen N.V.
12.2.1 Overview
12.2.2 Qiagen N.V.: Recent Developments
12.3 BioMerieux S.A.
12.3.1 Overview
12.3.2 BioMerieux S.A.: Recent Developments
12.4 OraSure Technologies, Inc.
12.4.1 Overview
12.4.2 OraSure Technologies, Inc.: Recent Developments
12.5 Instrumentation Laboratory (a Werfen company)
12.5.1 Overview
12.5.2 Instrumentation Laboratory: Recent Developments
12.6 Becton Dickinson and Company
12.6.1 Overview
12.6.2 Becton dickenson and company: Recent Developments
12.7 Nova Biomedical
12.7.1 Overview
12.7.2 Nova Biomedical: Recent Developments
13 ANNEXURE
13.1 Abbreviations
Tables
Table 1 FUNDING SCENARIO
Table 1 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCTS, 2017–2024 ($MILLION)
Table 1 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE, 2017–2024 ($MILLION)
Table 2 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET REVENUE BY REGIONS, 2017–2024 ($MILLION)
Table 3 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET BY VENDOR RANKING, 2017
Table 4 OTHER PROMINENT VENDORS OF POINT-OF-CARE DIAGNOSTICS MARKET
Table 5 ABBOTT LABORATORIES: PRODUCT OFFERINGS
Table 6 ABBOTT LABORATORIES: RECENT DEVELOPMENTS
Table 7 F. HOFFMANN-LA ROCHE: OFFERINGS
Table 8 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS
Table 9 JOHNSON & JOHNSON: PRODUCT OFFERINGS
Table 10 JOHNSON & JOHNSON: RECENT DEVELOPMENTS
Table 11 DANAHER CORPORATION: OFFERINGS
Table 12 DANAHER CORPORATION: RECENT DEVELOPMENTS
Table 13 SIEMENS HEALTHINEERS INC.: RECENT DEVELOPMENTS
Table 14 SIEMENS HEALTHINEERS INC.: RECENT DEVELOPMENTS
Table 15 TRINITY BIOTECH PLC: SNAPSHOT
Table 16 QIAGEN N.V.: SNAPSHOT
Table 17 BIOMERIEUX S.A.: SNAPSHOT
Table 18 ORASURES TECHNOLOGIES: SNAPSHOT
Table 19 INSTRUMENTATION LABORATORY: SNAPSHOT
Table 20 BECTON DICKINSON AND COMPANY: SNAPSHOT
Table 21 NOVA BIOMEDICAL: SNAPSHOT
?
Charts
Chart 1 RESEARCH METHODOLOGY OF GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET
Chart 2 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET REVENUE, 2017–2024 ($MILLION)
Chart 3 PEST ANALYSIS OF GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET
Chart 4 PORTER 5 FORCES ON GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET
Chart 5 DRO – IMPACT ANALYSIS OF GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET
Chart 6 KEY STAKEHOLDERS
Chart 7 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET BY PRODUCT, 2017 V/S 2024 ($)
Chart 8 GLOBAL GLUCOSE MONITORING KITS MARKET REVENUE FORECAST, 2017–2024 ($MILLION)
Chart 9 GLOBAL INFECTIOUS DISEASE TESTING KITS MARKET REVENUE FORECAST, 2017–2024 ($MILLION)
Chart 10 GLOBAL PREGNANCY AND FERTILITY TESTING KITS MARKET REVENUE FORECAST, 2017–2024 ($MILLION)
Chart 11 GLOBAL HEMATOLOGY TESTING KITS MARKET REVENUE FORECAST, 2017–2024 ($MILLION)
Chart 12 GLOBAL CARDIOMETABOLIC MONITORING KITS MARKET REVENUE FORECAST, 2017–2024 ($MILLION)
Chart 13 GLOBAL URINALYSIS TESTING KITS MARKET REVENUE FORECAST, 2017–2024 ($MILLION)
Chart 14 GLOBAL COAGULATION MONITORING KITS MARKET REVENUE FORECAST, 2017–2024 ($MILLION)
Chart 15 GLOBAL TUMOUR OR CANCER MARKER TESTING KITS MARKET REVENUE FORECAST, 2017–2024 ($MILLION)
Chart 16 GLOBAL CHOLESTEROL TESTING KITS MARKET REVENUE FORECAST, 2017–2024 ($MILLION)
Chart 17 GLOBAL DRUGS OF ABUSE TESTING KITS MARKET REVENUE FORECAST, 2017–2024 ($MILLION)
Chart 18 GLOBAL OTHERS MARKET REVENUE FORECAST, 2017–2024 ($MILLION)
Chart 19 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET BY PRESCRIPTION MODE, 2017 (%)
Chart 20 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET BY PRESCRIPTION MODE, 2024 (%)
Chart 21 GLOBAL PRESCRIPTION-BASED POINT-OF-CARE DIAGNOSTICS MARKET REVENUE FORECAST, 2017–2024 ($MILLION)
Chart 22 GLOBAL OTC-BASED POINT-OF-CARE DIAGNOSTICS MARKET REVENUE FORECAST, 2017–2024 ($MILLION)
Chart 23 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET BY END-USERS SEGMENTATION, 2017 (%)
Chart 24 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET BY GEOGRAPHICAL SEGMENTATION, 2017 (%)
Chart 25 POINT-OF-CARE DIAGNOSTICS MARKET REVENUE IN NORTH AMERICA, 2017–2024 ($MILLION)
Chart 26 POINT-OF-CARE DIAGNOSTICS MARKET REVENUE IN EUROPE, 2017–2024 ($MILLION)
Chart 27 POINT-OF-CARE DIAGNOSTICS REVENUE IN ASIA-PACIFIC, 2017–2024 ($MILLION)
Chart 28 POINT-OF-CARE DIAGNOSTICS MARKET REVENUE IN REST OF THE WORLD, 2017–2024 ($MILLION)
Chart 29 ABBOTT LABORATORIES.: OVERVIEW SNAPSHOT
Chart 30 ABBOTT LABORATORIES.: BUSINESS UNITS
Chart 31 ABBOTT LABORATORIES: GEOGRAPHIC PRESENCE
Chart 32 ABBOTT LABORATORIES.: SWOT ANALYSIS
Chart 37 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT
Chart 38 JOHNSON & JOHNSON: BUSINESS UNITS
Chart 39 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE
Chart 40 JOHNSON & JOHNSON: SWOT ANALYSIS
Chart 41 DANAHER CORPORATION: OVERVIEW SNAPSHOT
Chart 42 DANAHER CORPORATION: BUSINESS UNITS
Chart 43 DANAHER CORPORATION: GEOGRAPHIC PRESENCE
Chart 44 DANAHER CORPORATION: SWOT ANALYSIS
Chart 45 SIEMENS AG: OVERVIEW SNAPSHOT
Chart 46 SIEMENS AG: BUSINESS UNITS
Chart 47 SIEMENS AG: GEOGRAPHIC PRESENCE
Chart 48 SIEMENS HEALTHINEERS INC.: SWOT ANALYSIS
